IgAN

Advertisement
Charlotte RobinsonERA Congress 2025 | June 9, 2025
Phase 3 VISIONARY trial data showed sibeprenlimab helps achieve significant proteinuria reduction in IgAN.
Charlotte RobinsonERA Congress 2025 | June 11, 2025
Treatment effects of nefecon were consistent independent of baseline eGFR among patients with IgAN.
Victoria SochaIgA Nephropathy | June 6, 2025
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found.
Charlotte RobinsonERA Congress 2025 | June 5, 2025
Research identified the optimal biomarker combination to predict interstitial fibrosis surface in IgA nephropathy.
Charlotte RobinsonERA Congress 2025 | June 5, 2025
Long-term data demonstrated that zigakibart reduced proteinuria and stabilized kidney function of patients with IgAN.
Victoria SochaIgA Nephropathy | June 5, 2025
Moderate-to-severe chronic arteriolar lesions were found to be independent risk factors for adverse renal prognosis in IgAN.
Katie KoskoIgA Nephropathy | May 20, 2025
A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.
Katie KoskoIgA Nephropathy | May 19, 2025
Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.
Katie KoskoIgA Nephropathy | May 15, 2025
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgAN, a study found.
Katie KoskoIgA Nephropathy | May 14, 2025
Several genetically predicted environmental factors increase the risk of IgAN and membranous nephropathy, a study found.
Victoria SochaIgA Nephropathy | May 14, 2025
An analysis Identified SIRT1, BAG3, COKN1A and FOS as potential autophagy-related biomarkers for IgAN.
Victoria SochaIgA Nephropathy | May 14, 2025
Research identified microRNA-483-5p as a possible biomarker for IgA nephropathy to help with risk stratification.
Charlotte RobinsonIgA Nephropathy | May 1, 2025
The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy.
Richard Lafayette, MDIgA Nephropathy | May 1, 2025
We spoke with ALIGN study investigator Richard Lafayette, MD, upon the FDA's accelerated approval of atrasentan for IgAN.
Victoria SochaNKF Spring Clinical Meetings 2025 | April 16, 2025
Researchers at SCM25 presented interim results of the SPARTAN trial of sparsentan as a treatment for patients with IgAN.
Victoria SochaNKF Spring Clinical Meetings 2025 | June 13, 2025
One-year results of the AFFINITY trial of atrasentan to treat proteinuria among patients with IgAN were presented at SCM25.
Charlotte RobinsonNKF Spring Clinical Meetings 2025 | April 13, 2025
Researchers shared baseline characteristics of patients in the phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy.
Charlotte RobinsonIgA Nephropathy | June 13, 2025
Otsuka filed a Biologics License Application with the FDA for sibeprenlimab for the treatment of IgA nephropathy (IgAN).
Freely FilteredNephrology Times | June 11, 2025
The Freely Filtered Filtrate discusses the top nephrology stories of 2024, including FLOW, cyberattacks, and IgAN trials.
Charlotte RobinsonDiabetes and Hypertension | June 13, 2025
SC0062 met the 12-week primary end point of a reduction in proteinuria in a study cohort with diabetic kidney disease (DKD).
Advertisement